Europe’s leading cancer conference may be swimming in antibody-drug conjugate (ADC) data, but AstraZeneca remains convinced ...

Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China’s Hansoh ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...

T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...

The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...

President Donald Trump has telegraphed a new round of 100% tariffs on all Chinese imports beginning in November. The U.S. has ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...

The biotech provided an update after the stock market closed Thursday, telling investors that it had been unable to align ...